Evidence brief · printable

Multiple Sclerosis evidence brief

One page, every section sourced. Print it or bring it on your phone.

Print or save as PDF Fits on one A4 or Letter page.

Multiple Sclerosis: evidence brief

Open Source Medicine Foundation · page built 16 November 2026 · trial data searched 2026-11-16 (capped at 1,000 of 1,529 matching trials) · https://research.opensourcemed.info/briefs/multiple-sclerosis.html

Research information, not medical advice. Prepared to support a conversation with a clinician, not to choose a treatment.

Live version

Medicines with registered trials

Scale: trials listed for each medicine on the tracker's condition page, a snapshot of ClinicalTrials.gov. A trial means it is being studied, not that it works.

  • Interferon beta-1b (Betaseron, BAY86-5046) 4 trials
  • Rebif® 2 trials
  • ACTH (see NCT02315872) 1 trial
  • Anti-Mullerian hormone (AMH) level 1 trial
  • Cetrizine 1 trial
  • Diphenhydramine 1 trial

Non-drug approaches tested

Scale: trial status on ClinicalTrials.gov (completed, results posted). Status is not a result.

  • Transcranial brain stimulation (tDCS, TMS) 43 trials · 16 completed · 11 with results
  • Aerobic and endurance exercise 60 trials · 28 completed · 4 with results
  • Education, coaching and self-management 35 trials · 19 completed · 3 with results
  • Mindfulness, meditation and relaxation 17 trials · 8 completed · 3 with results
  • Psychotherapy, counselling and peer support 20 trials · 10 completed · 2 with results
  • Cognitive behavioural and related therapies 16 trials · 9 completed · 2 with results

Natural products (RepurpOS Moderate tier)

Scale: RepurpOS evidence tier, from linked trials and literature. Product quality and dose vary.

  • Ginkgo Biloba
  • Vitamin D3
  • Melatonin
  • Coenzyme Q10
  • L-Carnitine
  • Cannabidiol (CBD)

Biomarkers reported

Direction in patients compared with the stated comparison group, as reported in the cited study.

  • 25-Hydroxyvitamin D lower · Clarke et al. 2020
  • CSF IgG Index higher · Saadeh et al. 2022
  • CSF Kappa Free Light Chains higher · Vecchio et al. 2024
  • CSF Oligoclonal Bands higher · Mukherjee et al. 2025
  • GFAP higher · Chitnis et al. 2025
  • Neurofilament Light Chain (NfL) higher · Chitnis et al. 2025

Trials recruiting

Status as recorded on ClinicalTrials.gov when searched (2026-11-16); check the registry for current status and eligibility.

  • An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function… NCT06675955
  • A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis NCT07067463
  • Study of Ovarian Reserve Concerning Patients With Multiple Sclerosis (MS), Compared… NCT05754593
  • Clinical Applications of Advanced Ophthalmic Imaging NCT03135327
  • Confirmatory Trial for Alleviating Fatigue in Multiple Sclerosis NCT06441617
  • Montpellier PROspective Cohort in Relapsing Remitting Multiple Sclerosis Using… NCT05962177

What we don't know yet

Gaps in registered trials, from the evidence-gap map. A gap is not a recommendation.

  • Exercise and physical activity: symptom severity and disease activity 26 trials, no results posted yet
  • Rehabilitation and therapy services: cognition 22 trials, no results posted yet
Sources: ClinicalTrials.gov (trials, status, posted results); RepurpOS natural-product tiers (registry trials, PubMed, reference databases); OSMF biomarker atlas where available; OSMF non-drug evidence map (607 non-drug trials for this condition). Lists are shortened; the live pages carry every entry with its source: evidence-gap map · RepurpOS · condition page · biomarker atlas. Counts change daily. Nothing here is a recommendation to start, stop or change any treatment.